Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 261 results for "Tecfidera Treated Patients"

PML Death Reported in Patient Treated With Dimethyl Fumarate

—FDA today announced upcoming changes to the labeling of dimethyl fumarate after the death of the patient who was taking the drug for the treatment of multiple sclerosis (MS). According to FDA, the patient, a 54-year-old woman, was ... ASHP, 2 months ago
FDA News

FDA Issues Warning About Brain Infection Tied to Multiple Sclerosis Drug

The U.S. Food and Drug Administration (FDA) is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate), developed a rare and serious brain infection called PML, and later died. As a result, ...
 Advance for Nurses1 month ago FDA Warns of Rare Brain Infection Associated With MS Drug Tecfidera  FDA News1 month ago FDA Issues Drug Safety Communication for Multiple Sclerosis Drug Tecfidera  HCPLive1 month ago FDA adds warning to Tecfidera label after patient death  Pharma Letter2 months ago

Biogen's Tecfidera Label Updated After Rare Brain Infection Case

The label for Biogen Idec Inc. (BIIB) 's multiple sclerosis drug Tecfidera will be updated with information about a patient who died of a rare brain infection while taking the medicine, U.S. regulators said today. The drug label, which gives ...
 Bloomberg2 months ago FDA amends label of Biogen Idec's Tecfidera to warn of a case of PML  FirstWord Pharma2 months ago Why Tecfidera Drug Label Is Updated...  RTTNews.com2 months ago

Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany

Tecfidera® is a product containing dimethyl fumarate (DMF) as the active ingredient for the treatment of MS. It was approved by the European Commission in January 2014. Worldwide sales of Tecfidera® as reported by Biogen Idec for the previous 4 ...
 Morningstar.com2 months ago Forward Pharma Files Lawsuit Against Biogen Over Tecfidera Sales In Germany  RTTNews.com2 months ago Forward Pharma : Sues Biogen Idec Over Tecfidera(R) Sales in Germany  4 Traders2 months ago

U.S. Claims Data Show That Biogen Idec's Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients

BURLINGTON, Mass. , Nov. 24, 2014 /PRNewswire/ --Decision Resources Group finds that, according to U.S. patient-level claims data, Biogen Idec's Tecfidera, the third-to-market oral disease modifying therapy (DMT) for multiple sclerosis (MS), ...
 Crawford Financial Planning2 months ago

Tecfidera now available from the NHS in England and Wales

From today Tecfidera , a treatment for relapsing remitting MS , will be made available on the NHS in England and Wales; it is already available in Northern Ireland and Scotland. Greater choice This means there are now 10 MS medicines available ...
 Multiple Sclerosis Society2 months ago
Boston Globe

Biogen drug for multiple sclerosis shows promise in repairing eye nerve damage

Biogen Idec Inc.'s experimental drug for multiple sclerosis showed signs that it could help repair nerve damage in patients eyes, a tentatively positive step for a drug aimed at reversing progression of the disease. In a mid-stage trial of 82 ...
 Boston Globe2 weeks ago Biogen MS Drug Shows Some Promise in Repairing Eye Nerve Damage  BusinessWeek2 weeks ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 2, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago
Motley Fool

3 Large Cap Biotech Stocks That Could Surprise Investors in 2015

Source: Celgene Corp. The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather ...
 Motley Fool1 month ago

Why Biogen Idec Inc. Stock Catapulted 10% Higher in December

What: Shares of Biogen Idec (NASDAQ: BIIB ) , a biotech juggernaut primarily focused on treating multiple sclerosis and autoimmune disorders, scorched higher by 10% in December, based on data from S&P Capital IQ , on the heels of positive clinical ...
 Citybizlist3 weeks ago Why Has Biogen (BIIB) Stock Been Trading Down?  Bidness Etc2 months ago Biogen: Big Biotech Play Ready To Move  Seeking Alpha1 month ago Market Update (NASDAQ:BIIB): Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE and ALPROLIX® at ASH Annual Meeting  Jutia Group1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less